|
 |
|
|||||||
|
|||||||||
© 2005 by the American Diabetes Association, Inc.
Emerging Treatments and Technologies |
A Double-Blind, Randomized, Dose-Response Study Investigating the Pharmacodynamic and Pharmacokinetic Properties of the Long-Acting Insulin Analog Detemir
1 Department of Internal Medicine, Diabetes and Metabolism, Medical University Graz, Graz, Austria
2 Institute of Medical Technologies and Health Management, Joanneum Research, Graz, Austria
3 Novo Nordisk, Bagsvaerd, Denmark
Address correspondence and reprint requests to Thomas R. Pieber, MD, Department of Internal Medicine, Medical University Graz, Auenbruggerplatz 15, A-8036 Graz, Austria. E-mail: thomas.pieber{at}meduni-graz.at
OBJECTIVE—To investigate the pharmacodynamic profile and duration of action for five subcutaneous doses of insulin detemir (0.1, 0.2, 0.4, 0.8, and 1.6 units/kg; 1 unit = 24 nmol) and one subcutaneous dose of NPH insulin (0.3 IU/kg; 1 IU = 6 nmol).
RESEARCH DESIGN AND METHODS—This single-center, randomized, double-blind, six-period, crossover study was carried out as a 24-h isoglycemic clamp (7.2 mmol/l) in 12 type 1 diabetic patients.
RESULTS—Duration of action for insulin detemir was dose dependent and varied from 5.7, to 12.1, to 19.9, to 22.7, to 23.2 h for 0.1, 0.2, 0.4, 0.8, and 1.6 units/kg, respectively. Interpolation of the dose-response relationships for AUCGIR (area under the glucose infusion rate curve) revealed that a detemir dose of 0.29 units/kg would provide the same effect as 0.3 IU/kg NPH but has a longer duration of action (16.9 vs. 12.7 h, respectively). Lower between-subject variability was observed for insulin detemir on duration of action (0.4 units/kg insulin detemir vs. 0.3 IU/kg NPH, P < 0.05) and GIRmax (maximal glucose infusion rate) (0.2 and 0.4 units/kg insulin detemir vs. 0.3 IU/kg NPH, both P < 0.05). Assessment of endogenous glucose production (EGP) and peripheral glucose uptake (PGU) resulted in an AOCEGP (area over the EGP curve) of 636 mg/kg (95% CI 279–879) vs. 584 (323–846) and an AUCPGU (area under the PGU curve) of 173 (47–316) vs. 328 (39–617) for 0.29 units/kg detemir vs. 0.3 IU/kg NPH, respectively.
CONCLUSIONS—This study shows that insulin detemir provides a flat and protracted pharmacodynamic profile.
Abbreviations: AOC, area over the curve • AUC, area under the curve • EGP, endogenous glucose production • GIR, glucose infusion rate • NEFA, nonesterified fatty acid • PGU, peripheral glucose uptake
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  M. J. Fowler Diabetes Treatment, Part 3: Insulin and Incretins Clin. Diabetes, January 1, 2008; 26(1): 35 - 39. [Full Text] [PDF]
|
|
|
|
 |
|
 F. Porcellati, P. Rossetti, N. R. Busciantella, S. Marzotti, P. Lucidi, S. Luzio, D. R. Owens, G. B. Bolli, and C. G. Fanelli Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes: A double-blind, randomized, crossover study Diabetes Care, October 1, 2007; 30(10): 2447 - 2452. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Hassan Hyperglycemia management in the hospital setting Am. J. Health Syst. Pharm., May 15, 2007; 64(10_Supplement_6): S9 - S14. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Trujillo Insulin Analogs and Pregnancy Diabetes Spectr, April 1, 2007; 20(2): 94 - 101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. M Regan and D. B Dunger Use of new insulins in children Arch. Dis. Child. Ed. Pract., August 1, 2006; 91(2): ep47 - ep53. [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Mooradian, M. Bernbaum, and S. G. Albert Narrative Review: A Rational Approach to Starting Insulin Therapy Ann Intern Med, July 18, 2006; 145(2): 125 - 134. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |